Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.

Agilent Technologies, a leading company in the diagnostics and genomics sector, has announced a significant reorganization of its business segments. The company has moved its Cell Analysis Division from the Life Sciences and Applied Markets Group (LSAG) to the Diagnostics and Genomics Group (DGG) as of December 20, 2023. This strategic move aims to enhance growth opportunities for both segments. Despite the reorganization, Agilent will maintain its three business segments: LSAG, DGG, and Agilent CrossLab, all of which will continue to be reportable segments. The company will present its financial statements reflecting the new structure starting with the quarter ending January 31, 2024, with prior periods being recast to align with the changes. This information was disclosed in a Current Report on Form 8-K filed with the SEC, which includes selected segment information and is not intended for filing purposes under Section 18 of the Securities Exchange Act of 1934, nor is it to be incorporated by reference into any registration statement or other document.